MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical
Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 9, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for
Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET / 6:30am PT MENLO PARK, Calif.
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc., a biotech company harnessing the power of the innate immune system, today announced the appointment of Andrew Sharabi, M.D., Ph.D., as Chief Medical Officer and Chris Krueger, J.D., as Executive Chairman of its Board of Directors. Additionally, Primmune revealed the formation of its Melanoma Clinical Study Advisory Board to support the clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll-like receptor 7 (TLR7) agonist as an immunotherapy for solid tumors. “We are thrilled to welcome Dr. Sharabi as Chief Medical Officer. He brings a rare combination of clinical expertise in melanoma, head
Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme delivery SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ISP-002, the company’s investigational therapy for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The FDA grants RPD designation for serious or life-threatening diseases that primarily affect children 18 years old or younger and affect fewer than 200,000 people nationwide. RPD designation allows recipient companies, upon approval of their designated treatment, to be eligible for a Priority Review Voucher (PRV1), which may be used for priority review
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop , trial will focus on early-stage, treatment-naive patients, a key difference from AN2's previous studies in mycobacterium
Orphan Drug Designation for MPS II builds on Immusoft’s clinical progress in MPS I and supports expansion of its engineered B cell platform across multiple indications SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ISP-002, the Company’s investigational engineered B cell therapy for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, a rare and life-threatening lysosomal storage disorder. MPS II is caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS), which leads to the progressive accumulation of glycosaminoglycans throughout the body. The disease results in multi-system pathology, including skeletal abnormalities,
Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT) First of two boron-based oncology targets to enter development in early 2026 Announced research collaboration with GSK to advance